From 3 February 2025, the respiratory syncytial virus (RSV) vaccine Abrysvo will be available under the National Immunisation Program (NIP) for eligible pregnant women. Pharmacists can administer Abrysvo to pregnant women between 28 and 36 weeks of pregnancy to reduce the risk of severe RSV disease in infants. The vaccine provides passive protection to the foetus during pregnancy by transferring RSV-specific antibodies through the placenta.
PDL highlights that while the product information for Abrysvo indicates vaccine administration between 24 and 36 weeks of gestation, the Australian Tech…
